Encapsulated amyloid-beta peptides

• US 7,618,944 B2
• Filed: 02/29/2008
• Issued: 11/17/2009
• Est. Priority Date: 03/01/2007
• Status: Expired due to Fees

• Current Assignee: Intezyne Technologies
• Original Assignee: Intezyne Technologies
• Inventors: Skaff, Habib, Breitenkamp, Kurt, Sill, Kevin N.
• Primary Examiner(s): Tsang; Cecilia
• Assistant Examiner(s): Bradley; Christina
• Application Number:
  US12/040,774
• Publication Number:
  US 20080274965A1
• Time in Patent Office: 627 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 2039/6093 Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
• CPC Class Codes: A61K 38/1716 Amyloid plaque core protein
• CPC Class Codes: A61K 39/0007 Nervous system antigens; Prions
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof.

Claims

1. A micelle having an amyloid (1-42) peptide or fragment or mutant peptide thereof, encapsulated therein,

wherein the amyloid-beta (1-42) peptide or fragment or mutant peptide is selected from the group consisting of SEQ ID Nos:

1-20 and wherein the micelle comprises a multiblock copolymer selected from the following compounds of the formula;

7. A composition comprising the micelle according to any one of claims 1-6, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

8. The micelle according to any one of claims 1-6 having SEQ ID NO:

1 encapsulated therein.

9. The micelle according to any one of claims 1-6, having SEQ ID NO:

2, 3, 4, 5, 6 or 7 encapsulated therein.

10. The micelle according to any one of claims 1-6, having SEQ ID NO:

8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 encapsulated therein.

2. A micelle having an amyloid-beta (1-42) peptide or fragment or mutant peptide thereof, encapsulated therein,

wherein the amyloid-beta (1-42) peptide or fragment or mutant peptide is selected from the group consisting of SEQ ID NOs:

1-20 and wherein the micelle comprises a multiblock copolymer selected from the following compounds of the formula;

3. A micelle having an amyloid-beta (1-42) peptide or fragment or mutant peptide thereof, encapsulated therein,

wherein the amyloid-beta (1-42) peptide or fragment or mutant peptide is selected from the group consisting of SEQ ID NOs:

1-20 and wherein the micelle comprises a multiblock copolymer selected from the following compounds of the formula;

4. A micelle having an amyloid-beta (1-42) peptide or fragment or mutant peptide thereof, encapsulated therein,

wherein the amyloid-beta (1-42) peptide or fragment or mutant peptide is selected from the group consisting of SEQ ID NOs:

1-20 and wherein the micelle comprises a multiblock copolymer selected from the following compounds of the formula;

5. A micelle having an amyloid-beta (1-42) peptide or fragment or mutant peptide thereof, encapsulated therein,

wherein the amyloid-beta (1-42) peptide or fragment or mutant peptide is selected from the group consisting of SEQ ID NOs:

1-20 and wherein the micelle comprises a multiblock copolymer selected from;

6. A micelle having an amyloid-beta (1-42) peptide or fragment or mutant peptide thereof, encapsulated therein,

wherein the amyloid-beta (1-42) peptide or fragment or mutant peptide is selected from the group consisting of SEQ ID NOs:

1-20 and wherein the micelle comprises a multiblock copolymer selected from;